skip to Main Content

We are developing

Tomorrow’s immuno – modulators oncology therapy
A single platform for defeating cancer and much more.

We are HEPHAISTOS-Pharma

A preclinical stage Biotech company developing the next generation of oncology treatments that will be boost immune system to treat incurable cancers.

One need, one mission :

Immunotherapy has shown impressive results in the past 5 years by treating cancers like never seen before. Unfortunately, success level are still very low and only 10% of patients can be cured today.

Our mission is to take Immunotherapy to the next level of efficiency by stimulating patients immune response and turning hidden cold tumors into hot targets for our immune system.


International experts & experimented operational team


Chairwoman & CSO

Martine CAROFF
DSc., Inventor, TLR4 agonist biochemistry expert. EU Woman Innovators Prize 2019.



Frederic CAROFF
MSc Centrale Paris, MBA Essec, Biotech Manager, Business Developer, Industrial scale up expert


CMC Manager

PhD, Head of Research Ability. Chemistry and Mass Spectrometry expert.

Jerome-Kerzerho-NB-190x190 (1)

Preclinical plan Manager

PhD, Immunologist, Collaborative project manager, Immuno-oncology expert.

Simon PIco 2 NB

Business Developer

Simon PICO
PhD, MBA EMLyon, Biotech Ecosystem expert, Business Angel

Advisory Board


Pr. Charles Dumontet,
Deputy Director CRCL Physician in Hematology. Oncology KOL.

Pr. of Hematology in University of Lyon Deputy Director CRCL. President of the Clinical Research and Innovation Department and also Vice-President of Research at HCL

jean-yves-blay NB

Pr. Jean-Yves Blay,
General Director at the Centre Léon Bérard, Oncology KOL.

President of the French Federation of Cancer Centers Unicancer, coordinator of European Reference Network on rare adult cancers, EURACAN


Dr. Nathalie Garçon, CEO and CSO BIOASTER, Adjuvant KOL

PharmD. PhD. Former Vice President, Head of the Adjuvant and Technology Innovation Center at GSK Vaccines, 2014 Stanley Plotkin Award for lifetime achievement in vaccines

olivier favre-bulle NB

Dr. Olivier Favre-Bulle,
CEO at 3BIOTECH Consulting, CMC Expert

Chemical Engineer, Bio-engineering PhD, MBA, Former Project manager at Sanofi, Covanc,  Novo Nordisk, CMC Consultant.

Market Needs

Turning cold tumors into hot tumors

Only 10% of current immunotherapies are successful
Need for stronger and safer immuno-modulators
to turn cold tumors into hot tumors and improve cancer therapy

Innovation & advantages

Onco-Boost platform

ONCO-Boost is the Fisrt-In-Class Immunostimulant injectable intravenous able to treat metastatic and hardly accessible cancer like Osteorcoma

Mechanism of Action

Mechanism of Action (MoA)


will stimulate monocytes, and dendritic cells to recruit and mature other immune defenses like CD4 T Cells, CD8 T Cells and macrophages.

Antibody (mAb)

will block friendly recognition pathways between Tumor cells and host Cells allowing immune defenses to see Tumor as a target to destroy.

All together

By recruiting and stimulating immune cells, ONCO-Boost enable treatment of tumors that were not previously sensitive to mAb’s action and open the way to treat incurable cancers.


Immuno Oncology

ONCO-Boost Immunotherapy

Human Vaccine

VAXI-Boost natural adjuvant


iNov Competition Winner

🇺🇸🇬🇧 🏆  We are very proud to announce…

Read more

University Paris Saclay

HEPHAISTOS-Pharma was present at the Event organized by…

Read more

Come in we’re hiring

HEPHAISTOS is currently hiring a Preclinical Development Manager,…

Read more

Clusters & Partners


HEPHAISTOS-Pharma is financed by the European Union FEDER regional fund

HEPHAISTOS-Pharma is financed by the WILCO Healthcare startup cluster.

HEPHAISTOS-Pharma is financed by the European Union and aims at becoming a breakthrough innovative Biotech in oncology, reaching clinical Phase 1 within 2 years. The ONCO-Boost project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 868937

HEPHAISTOS-Pharma’s academic partner CRCL is financed by the Region Auvergne-Rhône-Alpes, the Grand Lyon Metropole and the CLARA Canceropole.






    Back To Top